Life Sciences

13 September 2017

PsyOmics – follow-on investment

By |September 13th, 2017|

We are delighted to announce that the University of Cambridge Enterprise Fund V and the Parkwalk Opportunities Fund have invested in a follow-on financing round in PsyOmics, a spin-out from the Department of Chemical Engineering and Biotechnology.

The company aims to utilise blood-based diagnostics to increase the speed of diagnosis and to reduce misdiagnosis for […]

19 May 2017

Horizon Discovery – Parkwalk UCEF I exit

By |May 19th, 2017|

We are delighted to have generated a 2.36x return (3.37x inclusive of initial tax reliefs) for our investors on the sale of the University of Cambridge Enterprise Fund I holding in Horizon Discovery plc. The investment was held for 3.9 years and the exit was generated through a single block trade.
We would like to thank […]

Predictimmune – Parkwalk closes investment

By |May 16th, 2017|

We are delighted to announce that the Parkwalk Opportunities Fund and the University of Cambridge Enterprise Fund IV have completed an investment in Predictimmune Limited, a spinout company from the University of Cambridge.
Predictimmune is developing prognostic tests for immune-mediated conditions to aid their management and improve patient outcomes. Their first offering, PredictImmune-CD, will be […]

8 April 2017

Azul Optics – University of Bristol Enterprise Fund I investment

By |April 8th, 2017|

We are delighted to announce that the University of Bristol Enterprise Fund I, managed by Parkwalk, has invested in Azul Optics.

Azul Optics is developing a device that can rapidly assess macular pigment density. The device will be affordable, fast, easy-to-use and compact, making it easy to integrate macular pigment density screening into regular eye exams. […]

Sphere Fluidics accepted onto the London Mayor’s International Business “Go to Grow” Programme to assist with business scaling.

By |April 4th, 2017|

28 February 2017

Parkwalk closes PhoreMost follow-on investment

By |February 28th, 2017|

We are pleased to announce that Parkwalk has made an investment in Phoremost, a Cambridge University spinout, as part of a Series ‘B’ round of equity funding, alongside Amadeus Capital Partners and the University. Phoremost’s mission is to accelerate, diversify and rationalise drug discovery.

PhoreMost has developed a next-generation phenotypic screening platform called ‘SiteSeeker’ to identify […]

Congenica – Parkwalk closes investment

By |February 15th, 2017|

We are delighted to announce that the Parkwalk Opportunities Fund and the Parkwalk Technology Fund VII have invested in a $10m Series ‘B’ financing round for Congenica Limited, which spun out of the Wellcome Trust Sanger Institute and Department of Health. Congenica has developed software that enables the accurate, rapid and scalable clinical interpretation of […]

Sphere Fluidics – Parkwalk closes further funding round

By |February 15th, 2017|

We have closed a follow-on investment in Sphere Fluidics for the Opportunities Fund. This follows the UCEFs investing previously.

Sphere Fluidics is an established Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.

The company was founded on IP generated by the University of Cambridge and has […]

17 January 2017

Polypharmakos – University of Cambridge Enterprise Fund IV investment

By |January 17th, 2017|

Cambridge and Kew join forces to find new antimicrobial substances in plants
The Parkwalk-mamanged University of Cambridge Enterprise Fund IV and Cambridge Enterprise have invested £500k in Polypharmakos Limited, a spin-out from the University of Cambridge and the Royal Botanic Gardens, Kew.
Polypharmakos’s mission is to screen natural-product sources of plant, fungal and insect origin for […]

18 November 2016

Exonate – University of Bristol Enterprise Fund I investment

By |November 18th, 2016|

We are delighted to announce that the University of Bristol Enterprise Fund I, managed by Parkwalk, has invested in Exonate.

Exonate are developing a novel approach to modulating new vessel growth.  By controlling the balance of two contrasting forms of a protein called Vascular Endothelial Growth Factor (VEGF), they have demonstrated that they could not only treat models […]

20 September 2016

Horizon Discovery – Strong Revenue Growth and Focus on Operational Gearing Underpin Path to Profitability

By |September 20th, 2016|

Cambridge, UK, 20 September 2016: Horizon Discovery Group plc (LSE: HZD), a world leader in the application of gene editing technologies, announces its interim results for the six months ended 30 June 2016.
Highlights (including post period end):
Financial
·     Group revenue increased 19% to £10.2 million (HY15: £8.6 million)
·     Products business revenue increased 62% to £4.8 […]

10 August 2016

Micrima – University of Bristol Enterprise Fund I investment

By |August 10th, 2016|

We are delighted to announce that the University of Bristol Enterprise Fund I, managed by Parkwalk, has invested in Micrima.

The company intends to develop and commercialise a new Breast Imaging System (MARIA) aimed at radically improving breast cancer detection and survival rates through the provision of much safer, more frequent, more comfortable and less expensive […]

25 July 2016

Fluidic Analytics – University of Cambridge Enterprise Fund IV and Parkwalk investment

By |July 25th, 2016|

Parkwalk have recently closed an investment in Fluidic Analytics for the University of Cambridge Enterprise Fund IV and Parkwalk Funds.

Fluidic Analytics is developing a line of tools for the rapid, accurate, cost-effective analysis of proteins and other biomolecular species. By combining a powerful microfluidics platform developed at the University of Cambridge with efficient manufacturing and design principles, […]

PsyOmics – University of Cambridge Enterprise Fund IV investment

By |July 7th, 2016|

We are delighted to announce that the University of Cambridge Enterprise Fund IV, managed by Parkwalk, has invested in PsyOmics, a spin-out from the Department of Chemical Engineering and Biotechnology.

The company aims to utilise blood-based diagnostics to increase the speed of diagnosis and to reduce misdiagnosis for mental health patients.

Mental illness accounts for over […]

21 April 2016

DefiniGEN – Parkwalk closes follow on investment

By |April 21st, 2016|

Parkwalk closes DefiniGen investment for the University of Cambridge Enterprise Fund IV and Parkwalk Funds

DefiniGEN, a spin-out from the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital, have created a stem cell technology to provide human cells to the drug discovery sector for use in lead optimisation and toxicity programmes.

The Company’s proprietary production […]

9 March 2016

Sphere Fluidics – University of Cambridge Enterprise Fund III closes further funding round

By |March 9th, 2016|

We have closed an investment, in a $7m funding round, in Sphere Fluidics for the University of Cambridge Enterprise Fund III. This follows the UCEFs I and II investing previously. The investment round has been led by an Asian corporate investor

Sphere Fluidics is an established Life Sciences company which has developed unique products for use in single cell analysis […]

21 December 2015

Oxford Endovascular – Parkwalk closes University of Oxford Isis Fund investment

By |December 21st, 2015|

We are delighted to announce that the University of Oxford Isis Fund II has completed an investment in Oxford Endovascular Limited, a company developing sophisticated mesh tubes to treat patients suffering from brain aneurysms. Parkwalk invested in a £2m round alongside the new Oxford Sciences Innovation plc.

The Oxford technology uses a special laser-cut metal alloy which has a […]

20 August 2015

Parkwalk closes Xerion investment

By |August 20th, 2015|

We are pleased to announce that the University of Oxford Isis Fund II has made an investment in Xerion, a nanoparticle company spun-out of the University with a novel treatment for cancer.

Xerion seeks to commercialise Dr Helen Townley’s Research Group’s work into the use of nanoparticles in cancer for therapy, imaging and drug delivery.
The small […]

Parkwalk closes Quethera investment

By |August 13th, 2015|

We are pleased to announce that the University of Cambridge Enterprise Fund III has made an investment in Quethera, a gene therapy company spun-out of the University with a novel treatment for glaucoma.

Quethera announces seed financing to develop gene therapy aimed at preventing blindness in glaucoma patients

CAMBRIDGE, UK, 17th September 2015: Quethera, a gene therapy […]

1 June 2015

Omega Diagnostics – Development Update

By |June 1st, 2015|

Omega Diagnostics Group PLC – Development Update – Visitect® CD4 and Allergy

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following development update on its infectious disease and allergy projects.

Infectious Disease – Visitect® CD4 update
Since the trading update on 15 April 2015, the Company has continued to […]